DUBLIN, Feb. 14,
2024 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will report its fourth quarter and full year 2023
financial results and provide a business update after market close
on Monday, February 26, 2024. An
accompanying conference call and simultaneous webcast will be
hosted at 5:00 pm ET (2:00 pm PT/10:00 pm
GMT) that day.
Conference Call Information
To participate in the live call by telephone, please
pre-register here. Those interested in listening to the conference
call live via the internet may do so by visiting Theravance
Biopharma's website at www.theravance.com, under the Investors
section, Events and Presentations.
A replay of the webcast will be available on Theravance
Biopharma's website for 30 days through March 27, 2024.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that
Make a Difference® in people's lives. In pursuit of its
purpose, Theravance Biopharma leverages decades of expertise, which
has led to the development of FDA-approved YUPELRI®
(revefenacin) inhalation solution indicated for the maintenance
treatment of patients with chronic obstructive pulmonary disease
(COPD). Ampreloxetine, its late-stage investigational
norepinephrine reuptake inhibitor in development for symptomatic
neurogenic orthostatic hypotension, has the potential to be a first
in class therapy effective in treating a constellation of cardinal
symptoms in multiple symptom atrophy patients. The Company is
committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the
Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and
certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing in this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
https://www.theravance.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-26-2024-302061365.html
SOURCE Theravance Biopharma, Inc.